Latanoprost Stada

Latanoprost, the active ingredient in Latanoprost Stada, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It is employed to lower intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension, helping to preserve visual function. It is administered once daily in the evening to achieve consistent pressure reduction.

GNH USA supplies Latanoprost Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assurance processes and regulatory approvals across EU and other markets.

Latanoprost is a prostaglandin analog used to manage conditions that involve elevated intra‑ocular pressure.

Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. Ocular hypertension: lowers pressure to prevent conversion to glaucoma. Normal‑tension glaucoma: provides pressure reduction even when baseline pressure is within normal range.

Latanoprost may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye redness or hyperemia. - Increased eyelash length and density. - Darkening of the iris pigment. - Eye irritation or foreign‑body sensation. - Transient blurred vision. - Mild eye discomfort.

Serious or Rare Side Effects: - Severe ocular inflammation (uveitis). - Allergic reactions such as swelling or rash. - Sudden loss of vision. - Macular edema. - Ocular infection. - Systemic hypersensitivity reactions.

Before using Latanoprost, consider the following safety measures.

Pregnancy: safety not established; avoid unless benefit outweighs risk. Breastfeeding: unknown; use with caution. Concurrent ocular surgery: may affect healing; discuss with surgeon. Contact lens wearers: may develop deposits; consider removal during treatment. Monitor intra‑ocular pressure: assess response after initiation. Store at ambient temperature: keep bottle in original packaging, protect from light and moisture.

Latanoprost can interact with other ophthalmic agents.

Major Interactions (Avoid): - Concomitant use of other prostaglandin analogs: risk of excessive hypotony. - Non‑steroidal anti‑inflammatory eye drops: may reduce efficacy. - Systemic carbonic anhydrase inhibitors: may diminish IOP reduction.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive IOP‑lowering effect. - Corticosteroid eye drops: may counteract Latanoprost action. - Anticholinergic agents: may affect pupil size and ocular dynamics.